DIA SIAC TMF Reference Model

Slides:



Advertisements
Similar presentations
Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
Advertisements

EPAA Annual conference November Regulatory acceptance of alternative approaches for pharmaceuticals Jean-Marc Vidal Safety & Efficacy of Human Medicines.
HOT TOPICS ARCHIVING OR HOW NOT TO DUMP YOUR RUBBISH!
Peter Griffith and Megan McGroddy 4 th NACP All Investigators Meeting February 3, 2013 Expectations and Opportunities for NACP Investigators to Share and.
Clinical QA Data Audits A GCP Point of View Linda Del Paggio GCP Compliance BioBridges, LLC.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Managing Sponsorship Research Services University of Oxford.
Good Clinical Practice GCP
Healing Hands Clinical Research Services is a Site Management organization with broad spectrum of activities.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
INTRODUCTION TO RA.
Trial Master File Reference Model Supported by the DIA Document and Records Management Special Interest Area Committee Karen Redding, Co-Chair.
Second Annual Japan CDISC Group (JCG) Meeting 28 January 2004 Julie Evans Director, Technical Services.
Trial Master File Reference Model Supported by the DIA Document and Records Management Special Interest Area Committee Published: 22 August 2012.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
The Road to Version 3 27 th October  Created and maintained through a group of DIA (Drug Information Association) volunteers ◦ ~350 contributors.
1 EARLY SAFETY MANAGEMENT OF PROJECTS AND EXPERIMENTS HSE UNIT PH DSO EDMS No
Part 11 Public Meeting PEERS Questions & Responses The opinions expressed here belong to PEERS members and not the corporate entities with which they are.
Trial Master File Reference Model
Good Clinical Practice (GCP) UKTMN 6 th June 2006.
Lifespan GOOD CLINICAL PRACTICE Record Management GCP May 2005.
Trial Master Files – the De-Centralised Communication Challenge Karen Roy.
Medical Writing Special Interest Area Community (SIAC) Medical Communications March Workshop 2012 David Clemow SIAC Chair Melissa Ossanna Communications.
1 DIA SIAC TMF Reference Model Lisa Mulcahy Karen Roy.
Regulated Product Submission Eileen M. Girten, MS i3 Statprobe 1DIA Education SIAC.
DIA Trial Master File Reference Model
GCP (GOOD CLINICAL PRACTISE)
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on the Somatic Cell.
Clinical Trials.
Paper Destruction Team Full Team Meeting 9 April 2013.
Responsibilities of Sponsor, Investigator and Monitor
Process-based Metadata From a DIA Presentation: eTMF – Migrating from Paper Trial Master Files to Electronic Eldin Rammell, Managing Director, Rammell.
The Trial Master File What is it? What’s in it? Lisa Mulcahy.
1 Brett Claffee 11-Mar-2011 Paper Destruction - Legal Topic Team Agenda
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
2009 DIA US Annual Meeting GCP Session Advisory Committee Meeting
Briefing on MHRA routine inspection of non-commercial clinical trials
Post MHRA Inspection What next?
Paper Destruction - Legal Topic Team
FDA's Two New Draft Guidance on Software and Device
Lisa Hoebelheinrich, JD, CHRC Associate Vice Chancellor, Compliance
Paediatric Medicine: The Paediatric Investigation Plan
2009 IOOS Regional Coordination Workshop Thursday, August 27
Track 11 Symposium 27 June :30 – 3:00 PM
Responsibilities of Sponsor, Investigator and Monitor
Nordic Cooperation on Ethical Review Procedures Nordforsk – nordic trial alliance MIKA SCHEININ
MAINTAINING THE INVESTIGATOR’S SITE FILE
2009 DIA US Annual Meeting GCP Session Advisory Committee Meeting
The Information Professional’s Role in Product Safety
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
DRM SIAC Paper Destruction Working Group 13 September 2011
Quality Subgroup Output
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
Administering Informed Consent Issues for Discussion
MANAGEMENT OF PROTOCOL AND GCP DEVIATIONS AND VIOLATIONS
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
IHE Eye Care Process and Timeline
Good Clinical Practice
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
Why the Industry Needs an EDM Reference Model
Setting Actuarial Standards
Presentation to the EPREV Lessons Learned Workshop
Humanitarian Assistance
MANAGEMENT OF PROTOCOL AND GCP DEVIATIONS AND VIOLATIONS
Introduction to TransCelerate
Fundamentals of Electronic Submissions and eCTD
MAINTAINING THE INVESTIGATOR’S STUDY FILE
WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:
Site File Management. Julie James, Aldona Kirkham Anne Moore UHL Clinical Trial Monitors and Trainers Sept 2017.
S A Overarching SOPs Funding Secured Training Records
Presentation transcript:

DIA SIAC TMF Reference Model Lisa Mulcahy Karen Roy Inaugural Meeting 23MAR2009

The Charter Why we need this group? What will our challenges be? What are we going to deliver? And by when? Who should be involved? 2

Charter: What is the TMF? The Trial Master File (TMF) contains those essential documents that individually and collectively permit the evaluation of the conduct of a trial and the quality of the data produced. These documents serve to demonstrate the compliance of the investigator, sponsor, and monitor with the standards of GCP and with all applicable regulatory requirements. (ICH Guideline for Good Clinical Practice, E 6, Chapter 8).

Charter: Why We Need This All companies running clinical trials in the pharmaceutical/biotech industry maintain a TMF for each clinical trial. Each company has their own unique TMF structure as defined by their SOPs. There exists no comprehensive common model for managing TMF documents. Many functions and vendors contribute to a TMF, each with their own interpretation and processes and oversight of the content on an ongoing basis is usually not one person’s or function’s responsibility.

Charter: The Challenges (1) Even though regulatory guidance exists such as ICH section 6, it addresses only a sub-set TMF documents. Documentation requirements for the set-up and maintenance of quality systems, electronic systems, safety monitoring, and proof of an adequate and well-controlled trial, to name a few, are in different parts of different regulations, for different countries or regions. A single, unified interpretation of the regulations by our project team, by our stakeholders, by Regulatory Agencies, and by the pharmaceutical industry will be some of our biggest hurdles we will need to overcome.

Charter: The Challenges (2) It is also paramount include opinions from Regulatory Agencies and other defining bodies who could either be contributors or stakeholders in standard TMF taxonomy and metadata. The TMF has a wide range of contributors and stakeholders, crossing over many DIA SIACs, as well as other Industry organizations e.g. QA, GCP, archiving, data management etc. It is imperative to get a wide-reaching input into this SIAC. The main challenge we are facing is the participation and adherence of the industry itself.

Charter: Scope With respect to the Content domain, the working group shall consider the full TMF with all applicable functional areas involved in clinical research and will not include the Preclinical, Non-clinical, and Chemical, Manufacturing & Controls functional areas.

Charter: The Deliverables and By When Finalize the Charter By end of April? Submission of abstract to EU EDM Conference (Vienna) Categorize the TMF into zones and define the content list of trial master file documents within these zones. By end of August? Integrate the TMF into EDM reference Model for content and associated metadata By end of November? EU EDM Conference in beginning of December Develop a parking lot for 2010 Goals and Objectives 8

Who Are We? Astellas, CSC, Elan, Consultant, Clinilabs, Safe BioPharm Association, Actelion, Novartis, Phlexglobal, i3Research, Massachusetts General Hospital, Talecris, Lundbeck, Spectrum, Daiichi-Sankyo, Sterling Bio, NextDocs, Centocor, Shire, Astellas, CRIX International Denmark, Switzerland, UK, USA Clinical, clinical document management, business development, regulatory operations, regulatory, compliance, archiving, 9

Who Do We Still Need? What other functional areas? DM, Statistics, MW, QA? Other DIA SIACs Other Associations – QA, GCP, Clinical, Archiving, Data Management Regulatory Agencies – US & Europe Stakeholders and Contributors 10

What is Our First Goal? To break the TMF down into manageable zones To allocate the zones to ‘zone leads’ To start to identify documents within each zone 11

Reference Model - Clinical Domain Format Output? Reference Model - Clinical Domain

Upcoming Activities Next meeting will be held in 2 weeks, on 6APR09 at 11A EDT. Our meetings from then forward will occur every 3weeks (April 27th, May 18th, June 8th, …) Meetings request will come from Michael McNair (DIA Volunteer Coordinator) through the DRM SIAC WebOffice